Top-News
Gesundheitswesen USA

Invitae Corp News

Aktie
WKN:  A14NKG ISIN:  US46185L1035 US-Symbol:  NVTAQ
0,001 $
-0,0025 $
-71,43%
20:28:43 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
286,49 Mio.
Marktkapitalisierung *
931,68 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 08.02.2024

Invitae Corp News

24.04.24 - PR Newswire
Labcorp Announces Winning Bid for Select Assets of Invitae
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire
22.04.24 - PR Newswire
Invitae Publishes its Environmental, Social and Governance (ESG) Report
Invitae Publishes its Environmental, Social and Governance (ESG) Report PR Newswire
13.02.24 - PR Newswire
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process PR Newswire
30.01.24 - PR Newswire
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics PR Newswire
22.01.24 - PR Newswire
Invitae Completes Sale of Reproductive Health Assets to Natera
Invitae Completes Sale of Reproductive Health Assets to Natera PR Newswire
13.12.23 - PR Newswire
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts PR Newswire
08.11.23 - PR Newswire
Invitae Reports Third Quarter 2023 Financial Results
Invitae Reports Third Quarter 2023 Financial Results PR Newswire
06.11.23 - PR Newswire
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships PR Newswire
01.11.23 - PR Newswire
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 PR Newswire
25.10.23 - PR Newswire
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-​Based Solutions to Reach Definitive Results PR ...
19.10.23 - PR Newswire
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer PR Newswire
12.10.23 - PR Newswire
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer PR Newswire
10.10.23 - PR Newswire
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics PR Newswire
03.10.23 - PR Newswire
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization PR Newswire
25.09.23 - PR Newswire
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO PR Newswire
22.09.23 - PR Newswire
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard
Invitae Receives Notice of Non-​Compliance with NYSE Minimum Share Price Continued Listing Standard PR Newswire
28.08.23 - PR Newswire
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer PR Newswire
15.08.23 - PR Newswire
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer PR Newswire
14.08.23 - PR Newswire
Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO
Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO PR Newswire
08.08.23 - PR Newswire
Invitae Reports Second Quarter 2023 Financial Results
Invitae Reports Second Quarter 2023 Financial Results PR Newswire

Newssuche

Videos

newspaper
08:55 Uhr
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »